Atossa Plans CVR Tied To Potential Rare Pediatric Disease Voucher

(RTTNews) - Atossa Therapeutics (ATOS) announced that its Board has approved a plan to issue one contingent value right (CVR) for each share of common stock, linking shareholders to potential proceeds from the company's first qualifying Rare Pediatric Disease Priority Review Vouc